Skip to main content
TipRanks
Go Ultimate75% OFF

Calidi Biotherapeutics (CLDI) Stock Statistics & Valuation Metrics

375 Followers

Total Valuation

Calidi Biotherapeutics has a market cap or net worth of $2.29M. The enterprise value is -$492.68K.

Market Cap
$2.29M
Enterprise Value
-$492.68K

Share Statistics

Calidi Biotherapeutics has 3,676,474 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
3,676,474
Owned by Insiders
9.92%
Owned by Institutions
1.00%

Financial Efficiency

Calidi Biotherapeutics’s return on equity (ROE) is -5.30 and return on invested capital (ROIC) is -314.38%.

Return on Equity (ROE)
-5.30
Return on Assets (ROA)
-2.25
Return on Invested Capital (ROIC)
-314.38%
Return on Capital Employed (ROCE)
-4.11
Revenue Per Employee
0
Profits Per Employee
-686.41K
Employee Count
29
Asset Turnover
0.00
Inventory Turnover
0.00

Valuation Ratios

The current PE Ratio of Calidi Biotherapeutics is -0.03. Calidi Biotherapeutics’s PEG ratio is -0.00.

PE Ratio
-0.03
PS Ratio
0.00
PB Ratio
0.91
Price to FCF
-0.14
Price to Operating Cash Flow
-0.09
PEG Ratio
-0.00

Income Statement

In the last 12 months, Calidi Biotherapeutics had revenue of 0 and earned -19.91M in profits. Earnings per share was -95.20.

Revenue
0
Gross Profit
-1.65M
Operating Income
-20.24M
Pretax Income
-20.05M
Net Income
-19.91M
EBITDA
-18.19M
Earnings Per Share (EPS)
-95.20

Cash Flow

In the last 12 months, operating cash flow was -15.85M and capital expenditures -53,000, giving a free cash flow of -15.90M billion.

Operating Cash Flow
-15.85M
Free Cash Flow
-15.90M
Free Cash Flow per Share
-6.42

Dividends & Yields

Calidi Biotherapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-720.98%
Earnings Yield
-1074.99%

Stock Price Statistics

Beta
1.01
52-Week Price Change
-97.49%
50-Day Moving Average
0.94
200-Day Moving Average
3.33
Relative Strength Index (RSI)
31.92
Average Volume (3m)
108.65K

Important Dates

Calidi Biotherapeutics upcoming earnings date is Mar 12, 2027, TBA (Not Confirmed).

Last Earnings Date
Nov 13, 2026
Next Earnings Date
Mar 12, 2027
Ex-Dividend Date
―

Financial Position

Calidi Biotherapeutics as a current ratio of 1.59, with Debt / Equity ratio of 68.21%

Current Ratio
1.59
Quick Ratio
1.59
Debt to Market Cap
0.12
Net Debt to EBITDA
0.17
Interest Coverage Ratio
-97.78

Taxes

In the past 12 months, Calidi Biotherapeutics has paid 15.00K in taxes.

Income Tax
15.00K
Effective Tax Rate
-0.00

Enterprise Valuation

Calidi Biotherapeutics EV to EBITDA ratio is 0.05, with an EV/FCF ratio of 0.05.

EV to Sales
0.00
EV to EBITDA
0.05
EV to Free Cash Flow
0.05
EV to Operating Cash Flow
0.05

Balance Sheet

Calidi Biotherapeutics has $3.95M in cash and marketable securities with $1.02M in debt, giving a net cash position of $2.92M billion.

Cash & Marketable Securities
$3.95M
Total Debt
$1.02M
Net Cash
$2.92M
Net Cash Per Share
$0.80
Tangible Book Value Per Share
$0.66

Margins

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

Gross Margin
0.00%
Operating Margin
0.00%
Pretax Margin
0.00%
Net Profit Margin
0.00%
EBITDA Margin
0.00%
EBIT Margin
0.00%

Analyst Forecast

The average price target for Calidi Biotherapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―

Price Target
―
Price Target Upside
―
Analyst Consensus
―
Analyst Count
―
Revenue Growth Forecast
―
EPS Growth Forecast
85.56%

Scores

Smart Score
―
AI Score
41